Stock Market Reviews

MXCT (MaxCyte, Inc.) News

Get the latest news, insights, and market updates on MXCT (MaxCyte, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
  SOUTH SAN FRANCISCO, Calif., December 01, 2025--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad’s app
  Dec 1, 2025 - $MXCT
• MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges
  MaxCyte Inc (MXCT) navigates a tough market with strategic partnerships and restructuring, while maintaining a strong cash position for future growth.
  Nov 13, 2025 - $MXCT
• MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
  ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance. Third Quarter and Recent Highlights Core business revenue of $6.4 million in the third quarter of 2025.Strategic Platform Lic
  Nov 12, 2025 - $MXCT
• MaxCyte Announces Planned CFO Transition in 2026
  Company initiates search for successorROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working c
  Nov 12, 2025 - $MXCT
• Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
  Avidity Biosciences (RNA) delivered earnings and revenue surprises of -20.95% and +399.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $MXCT
• ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
  ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 7, 2025 - $MXCT
• MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
  MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its prelimi
  Nov 5, 2025 - $MXCT
• MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
  ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the third quarter 2025 after the U.S. market close on Wednesday, November 5th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eas
  Oct 8, 2025 - $MXCT
• MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
  MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapiesROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclin
  Oct 6, 2025 - $MXCT
• MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
  ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company’s global workforce, inclusive of employees engaged through em
  Sep 22, 2025 - $MXCT